Secondary prevention of coronary heart disease in the elderly
Open Access
Abstract
These anxieties arise from two main sources: firstly, there is little evidence from randomised controlled trials to guide our decisions in the very elderly (over 80s); and secondly they differ in many ways from younger subjects. Table 1 ⇓ lists some differences in major and minor categories. The list is far from complete. Pharmacological treatment or lifestyle changes may be inappropriate in the demented patient, weight loss is more often a problem than a therapeutic goal, and dietary change may be resisted as may the standard exercise regimens. If the patient has so many problems you do not know which to address first, the prescription of a drug for secondary prevention may not be the place to start. Nevertheless there are patients without serious co-morbidity, with good cognitive functioning, and who do not wish to have another cardiac ischaemic episode. We must decide what to advise these patients. This article considers strategies applicable to the chronic treatment of a patient with established CHD and does not address the issue of treatment in the acute situation.Keywords
This publication has 23 references indexed in Scilit:
- Results of the pilot study for the Hypertension in the Very Elderly TrialJournal Of Hypertension, 2003
- Men and Women Differ in Lipoprotein Response to Dietary Saturated Fat and Cholesterol RestrictionThe Journal of Nutrition, 2003
- Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trialsThe Lancet, 2003
- n−3 Fatty acids and 5-y risks of death and cardiovascular disease events in patients with coronary artery diseaseThe American Journal of Clinical Nutrition, 2003
- Prevalence and management of coronary heart disease in primary care: population-based cross-sectional study using a disease registerJournal of Public Health, 2003
- Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trialThe Lancet, 2002
- MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trialThe Lancet, 2002
- Cardiovascular protection and blood pressure reduction: a meta-analysisThe Lancet, 2001
- Comparative Safety and Tolerability of Clopidogrel and AspirinDrug Safety, 1999
- The influence of cigarette smoking on prognosis after a first myocardial infarctionJournal of Chronic Diseases, 1978